vs
Side-by-side financial comparison of NewAmsterdam Pharma Co N.V. (NAMS) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
NewAmsterdam Pharma Co N.V. is the larger business by last-quarter revenue ($19.1M vs $18.6M, roughly 1.0× SCYNEXIS INC). SCYNEXIS INC runs the higher net margin — 65.7% vs -90.7%, a 156.4% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 740.1%).
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
NAMS vs SCYX — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $19.1M | $18.6M |
| Net Profit | $-17.4M | $12.3M |
| Gross Margin | — | — |
| Operating Margin | -186.1% | 56.3% |
| Net Margin | -90.7% | 65.7% |
| Revenue YoY | 740.1% | 1808.5% |
| Net Profit YoY | 55.5% | 376.5% |
| EPS (diluted) | $-0.15 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $18.6M | ||
| Q3 25 | — | $334.0K | ||
| Q2 25 | $19.1M | $1.4M | ||
| Q1 25 | — | $257.0K | ||
| Q4 24 | $12.8M | $977.0K | ||
| Q3 24 | $29.1M | $660.0K | ||
| Q2 24 | — | $736.0K | ||
| Q1 24 | — | $1.4M |
| Q4 25 | — | $12.3M | ||
| Q3 25 | — | $-8.6M | ||
| Q2 25 | $-17.4M | $-6.9M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | $-92.2M | — | ||
| Q3 24 | $-16.6M | $-2.8M | ||
| Q2 24 | — | $-14.5M | ||
| Q1 24 | — | $411.0K |
| Q4 25 | — | 56.3% | ||
| Q3 25 | — | -2516.5% | ||
| Q2 25 | -186.1% | -701.0% | ||
| Q1 25 | — | -3350.2% | ||
| Q4 24 | -338.5% | — | ||
| Q3 24 | -85.9% | -1563.6% | ||
| Q2 24 | — | -1255.0% | ||
| Q1 24 | — | -692.5% |
| Q4 25 | — | 65.7% | ||
| Q3 25 | — | -2572.2% | ||
| Q2 25 | -90.7% | -504.8% | ||
| Q1 25 | — | -2097.7% | ||
| Q4 24 | -721.7% | — | ||
| Q3 24 | -57.2% | -425.5% | ||
| Q2 24 | — | -1964.4% | ||
| Q1 24 | — | 29.9% |
| Q4 25 | — | $0.25 | ||
| Q3 25 | — | $-0.17 | ||
| Q2 25 | $-0.15 | $-0.14 | ||
| Q1 25 | — | $-0.11 | ||
| Q4 24 | $-0.91 | — | ||
| Q3 24 | $-0.18 | $-0.06 | ||
| Q2 24 | — | $-0.30 | ||
| Q1 24 | — | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $739.2M | $40.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $778.5M | $49.4M |
| Total Assets | $815.1M | $59.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $40.0M | ||
| Q3 25 | — | $37.9M | ||
| Q2 25 | $739.2M | $44.8M | ||
| Q1 25 | — | $40.6M | ||
| Q4 24 | $834.2M | $59.3M | ||
| Q3 24 | $422.7M | $68.8M | ||
| Q2 24 | — | $73.0M | ||
| Q1 24 | — | $80.2M |
| Q4 25 | — | $49.4M | ||
| Q3 25 | — | $36.4M | ||
| Q2 25 | $778.5M | $44.5M | ||
| Q1 25 | — | $50.5M | ||
| Q4 24 | $757.5M | $55.1M | ||
| Q3 24 | $378.9M | $58.5M | ||
| Q2 24 | — | $60.4M | ||
| Q1 24 | — | $74.1M |
| Q4 25 | — | $59.0M | ||
| Q3 25 | — | $51.1M | ||
| Q2 25 | $815.1M | $60.7M | ||
| Q1 25 | — | $67.9M | ||
| Q4 24 | $864.6M | $90.6M | ||
| Q3 24 | $439.2M | $99.0M | ||
| Q2 24 | — | $107.8M | ||
| Q1 24 | — | $118.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-37.7M | $18.4M |
| Free Cash FlowOCF − Capex | $-37.8M | — |
| FCF MarginFCF / Revenue | -197.2% | — |
| Capex IntensityCapex / Revenue | 0.5% | — |
| Cash ConversionOCF / Net Profit | — | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | $-119.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $18.4M | ||
| Q3 25 | — | $-8.7M | ||
| Q2 25 | $-37.7M | $-7.5M | ||
| Q1 25 | — | $-7.5M | ||
| Q4 24 | $-37.5M | $-24.0M | ||
| Q3 24 | $-12.5M | $765.0K | ||
| Q2 24 | — | $-10.9M | ||
| Q1 24 | — | $-4.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-37.8M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-37.5M | — | ||
| Q3 24 | $-12.6M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -197.2% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -293.5% | — | ||
| Q3 24 | -43.2% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.5% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 1.50× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NAMS
Segment breakdown not available.
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
